<DOC>
	<DOCNO>NCT01012830</DOCNO>
	<brief_summary>Use Huperzine-A , herbal supplement normally use treatment Alzheimer 's disease , potentially improve cognitive dysfunction ( memory problem ) functional capacity ( ability perform common daily task cook , bathing , telephone , shopping ) people schizophrenia .</brief_summary>
	<brief_title>Huperzine-A Help With Mental Problems Inability Care Onself Patients With Schizophrenia</brief_title>
	<detailed_description>HupA , alkaloid initially identify Chinese herbal medicine Huperia serrata , potent reversible acetyl cholinesterase ( AChE ) inhibitor additional unique property include NMDA-receptor antagonist property , neuroprotective antioxidant effect . In animal study , HupA show posse great inhibitory , longer-lasting , selective effect AChE activity donepezil . In clinical study HupA improve memory , mood , activity daily live patient Alzheimer 's dementia . Adverse effect report low rate clinical trial , mainly cholinergic , dizziness , nausea , gastrointestinal symptom , headache depress heart rate . Thus , HupA attractive option may beneficial effect cognitive also functional domain schizophrenia .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Huperzine A</mesh_term>
	<criteria>1. age 1959 2. diagnosis schizophrenia MINI 3. cognition score 1 standard deviation publish norm control 4. clinically stable 12 week i.e . antipsychotic ( ) 8 week stable dose least 4 week 5. moderate severity rating hallucination , delusion formal think disorder ( BPRS ) , negative symptom ( PANSS_N ) 6. minimal EPS ( SimpsonAngus &lt; 6 ) 7. minimal depression ( Calgary &lt; 10 ) 8. stable dose psychotropics ( 2 month ) 9. pregnant . 1. history active peptic ulcer disease within 1 year screen 2. clinically significant cardiac arrhythmia 3. rest pulse less 50 4. active cancer ( skin tumor melanoma exclude ) 5. history clinically significant stroke 6. current evidence history past 2 year epilepsy , focal brain lesion 7. start cholinesterase inhibitors/ cognitive enhancer ( galantamine , rivastigmine , donepezil , vitamin E memantine ) within 2 month screen , 8. use medication significant central nervous system anticholinergic activity within 2 month screen .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Cognitive Disorders</keyword>
	<keyword>Dementia</keyword>
	<keyword>Huperzine A</keyword>
	<keyword>HupA</keyword>
</DOC>